Is APHINITY the End of the Line for Trastuzumab Add-ons? Is APHINITY the End of the Line for Trastuzumab Add-ons?

The addition of pertuzumab to standard trastuzumab therapy in patients with early HER2-positive breast cancer led to modest improvements and increased side effects in the APHINITY trial.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news